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Introduction
Juvenile dermatomyositis (JDM) is a childhood autoim-
mune disease characterised by proximal muscle weakness
and cutaneous manifestations. Previous studies have iden-
tified an increase in circulating B cells in JDM patients,
but their provenance and functional characteristics have
not been examined. In this study we investigated whether
an immature B cell subset (CD24hiCD38hi), known to be
enriched for interleukin (IL)-10 producing regulatory
B cells (Breg)1, accounted for the expansion of circulating
B cells seen in JDM. The aryl hydrocarbon receptor (AhR)
is a ligand based transcription factor, which induces IL-10
expression in T cells2. We investigated the effects of mod-
ulating the AhR pathway on IL-10 expression in B cells.
Objectives
- To characterise the peripheral blood B cell compart-
ment in JDM patients with active disease and in disease
remission (according to the PRINTO criteria).
- To test the capacity of B cells from JDM patients to
produce IL-10 and ask if modulation of the AhR path-
way alters B cell IL-10.
Methods
54 patients were recruited through the UK JDM Cohort
and Biomarker Study. B cell subpopulations from periph-
eral blood mononuclear cells (PBMC) isolated from
healthy controls (HC) and JDM patients were analysed by
flow cytometry using the surface markers CD19, CD24,
CD38 and CD27. To detect B cell IL-10, PBMC were sti-
mulated for 72 hours with CD40 ligand (CD40L) trans-
fected CHO cells or the toll like receptor 9 agonist CpG
(ODN 2006) +/- Ahr antagonist (CH-223191), together
with PMA and ionomycin for the last 5 hours in the pre-
sence of Brefeldin A. Cells were then stained for CD19
and intra-cellular IL-10, which was detected by flow
cytometry.
Results
PBMC from JDM patients with active disease had a signifi-
cantly lower frequency of CD24hiCD38hi Breg when com-
pared to inactive JDM patients (median of 7.6% vs 12.9%
respectively, p=0.0109). Active patients had a lower fre-
quency of IL-10 producing B cells compared to inactive
patients and child controls (mean of 12.1%, 15.8% and
18.6% respectively), but this was only observed following
stimulation with CD40L and not CpG. Inhibition of AhR
following CD40L stimulation augmented IL-10 production
in JDM B cells, restoring it to normal levels. Blocking AhR
had no effects on CpG induced B cell IL-10.
Conclusion
These data identify a reduction in Breg in JDM patients
with active disease that was associated with defective
CD40L induced IL-10, when compared to child controls.
This defect was reversed following blockade of AhR.
These results suggest that over-activity of the AhR path-
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